MeiraGTx (MGTX) Competitors $5.82 -0.16 (-2.68%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MGTX vs. HARP, CBMG, VYGR, FRLN, RXRX, TARS, GLPG, XNCR, IMCR, and NRIXShould you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Harpoon Therapeutics (HARP), Cellular Biomedicine Group (CBMG), Voyager Therapeutics (VYGR), Freeline Therapeutics (FRLN), Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Galapagos (GLPG), Xencor (XNCR), Immunocore (IMCR), and Nurix Therapeutics (NRIX). These companies are all part of the "medical" sector. MeiraGTx vs. Harpoon Therapeutics Cellular Biomedicine Group Voyager Therapeutics Freeline Therapeutics Recursion Pharmaceuticals Tarsus Pharmaceuticals Galapagos Xencor Immunocore Nurix Therapeutics Harpoon Therapeutics (NASDAQ:HARP) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations. Which has more risk and volatility, HARP or MGTX? Harpoon Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Which has preferable valuation & earnings, HARP or MGTX? Harpoon Therapeutics has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarpoon Therapeutics$37.34M10.43-$67.73M-$8.76-2.63MeiraGTx$14.02M32.44-$84.03M-$1.21-4.81 Do analysts rate HARP or MGTX? Harpoon Therapeutics currently has a consensus target price of $23.00, suggesting a potential downside of 0.04%. MeiraGTx has a consensus target price of $23.50, suggesting a potential upside of 303.78%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts clearly believe MeiraGTx is more favorable than Harpoon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harpoon Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer HARP or MGTX? In the previous week, MeiraGTx had 7 more articles in the media than Harpoon Therapeutics. MarketBeat recorded 7 mentions for MeiraGTx and 0 mentions for Harpoon Therapeutics. Harpoon Therapeutics' average media sentiment score of 0.53 beat MeiraGTx's score of -0.28 indicating that Harpoon Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Harpoon Therapeutics Positive MeiraGTx Neutral Does the MarketBeat Community prefer HARP or MGTX? MeiraGTx received 97 more outperform votes than Harpoon Therapeutics when rated by MarketBeat users. Likewise, 71.54% of users gave MeiraGTx an outperform vote while only 59.12% of users gave Harpoon Therapeutics an outperform vote. CompanyUnderperformOutperformHarpoon TherapeuticsOutperform Votes9459.12% Underperform Votes6540.88% MeiraGTxOutperform Votes19171.54% Underperform Votes7628.46% Do insiders and institutionals hold more shares of HARP or MGTX? 74.0% of Harpoon Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 17.0% of Harpoon Therapeutics shares are held by insiders. Comparatively, 8.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is HARP or MGTX more profitable? Harpoon Therapeutics has a net margin of -81.68% compared to MeiraGTx's net margin of -633.05%. MeiraGTx's return on equity of -146.38% beat Harpoon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Harpoon Therapeutics-81.68% -893.55% -45.98% MeiraGTx -633.05%-146.38%-53.05% SummaryHarpoon Therapeutics and MeiraGTx tied by winning 9 of the 18 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get MeiraGTx News Delivered to You Automatically Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGTX vs. The Competition Export to ExcelMetricMeiraGTxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$454.83M$2.93B$5.04B$8.81BDividend YieldN/A1.89%5.16%4.07%P/E Ratio-4.8146.01130.5317.82Price / Sales32.44360.251,183.8674.55Price / CashN/A160.0933.6132.53Price / Book2.683.734.684.68Net Income-$84.03M-$41.63M$119.23M$226.08M7 Day Performance-12.35%-4.73%-1.83%-1.04%1 Month Performance-2.84%-6.53%-3.61%1.04%1 Year Performance6.20%25.63%31.74%26.28% MeiraGTx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGTXMeiraGTx4.3119 of 5 stars$5.82-2.7%$23.50+303.8%+2.8%$454.83M$14.02M-4.81300Analyst ForecastHARPHarpoon Therapeutics0.8619 of 5 stars$23.01flat$23.000.0%N/A$389.61M$37.34M-2.6353CBMGCellular Biomedicine GroupN/AN/AN/AN/A$384.69M$340,000.00-6.98217Analyst ForecastVYGRVoyager Therapeutics4.6613 of 5 stars$5.36+1.7%$17.00+217.2%-21.6%$287.88M$250.01M7.55100Analyst UpgradeAnalyst RevisionGap UpFRLNFreeline TherapeuticsN/A$6.48flat$6.50+0.3%N/A$28.12MN/A-1.16152RXRXRecursion Pharmaceuticals1.9932 of 5 stars$6.04-3.7%$9.25+53.1%-12.0%$1.80B$44.58M0.00400Analyst ForecastOptions VolumeHigh Trading VolumeTARSTarsus Pharmaceuticals1.8691 of 5 stars$46.58-0.7%$54.20+16.4%+166.2%$1.79B$17.45M-12.2350Analyst RevisionGLPGGalapagos1.2878 of 5 stars$25.64-3.9%$30.75+19.9%-31.4%$1.69B$259.40M0.001,123Analyst DowngradeShort Interest ↓Gap DownHigh Trading VolumeXNCRXencor3.5459 of 5 stars$23.72+0.4%$35.75+50.7%+19.3%$1.65B$168.34M0.00280IMCRImmunocore3 of 5 stars$32.42-0.4%$69.18+113.4%-28.7%$1.62B$296.31M-34.13497Positive NewsNRIXNurix Therapeutics2.5454 of 5 stars$22.64-0.7%$29.40+29.9%+247.8%$1.61B$76.99M0.00300 Related Companies and Tools Related Companies HARP Competitors CBMG Competitors VYGR Competitors FRLN Competitors RXRX Competitors TARS Competitors GLPG Competitors XNCR Competitors IMCR Competitors NRIX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
